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ABSTRACT
Tumor recurrence remains an obstacle after liver surgery, especially in living 
donor liver transplantation (LDLT) for patients with hepatocellular carcinoma 
(HCC). The acute-phase liver graft injury might potentially induce poor response 
to chemotherapy in recurrent HCC after liver transplantation. We here intended 
to explore the mechanism and to identify a therapeutic target to overcome such 
chemoresistance. The associations among graft injury, overexpression of IP10 and 
multidrug resistant genes were investigated in a rat liver transplantation model, and 
further validated in clinical cohort. The role of IP10 on HCC cell proliferation and tumor 
growth under chemotherapy was studied both in vitro and in vivo. The underlying 
mechanism was revealed by detecting the activation of endoplasmic reticulum 
(ER) stress signaling pathways. Moreover, the effect of IP10 neutralizing antibody 
sensitizing cisplatin treatment was further explored. In rat liver transplantation 
model, significant up-regulation of IP10 associated with multidrug resistant genes 
was found in small-for-size liver graft. Clinically, high expression of circulating 
IP10 was significant correlated with tumor recurrence in HCC patients underwent 
LDLT. Overexpression of IP10 promoted HCC cell proliferation and tumor growth 
under cisplatin treatment by activation of ATF6/Grp78 signaling. IP10 neutralizing 
antibody sensitized cisplatin treatment in nude mice. The overexpression of IP10, 
which induced by liver graft injury, may lead to cisplatin resistance via ATF6/Grp78 
ER stress signaling pathway. IP10 neutralizing antibody could be a potential adjuvant 
therapy to sensitize cisplatin treatment.
INTRODUCTION
Liver transplantation is a promising treatment for the 
patients with hepatocellular carcinoma (HCC), the 3 year 
survival rate of liver transplantation for HCC was up to 80% 
and the 5 year survival rate reached 75% [1–3]. However, 
the tumor recurrence is still the most serious threat to HCC 
patients after liver transplantation. Although many adjuvant 
therapies were applied to minimize the recurrent rate, the 
5-year tumor recurrent rates ranged from 8% to 56% [4–6]. 
Chemotherapy, as an alternative treatment for HCC, had a 
remarkable response rate in primary liver cancer [7–11]. 
However, it had no benefit on recurrent HCC patients [12]. 
The reason for this difference was still unclear.
Living donor liver transplantation presents greater 
risks of liver graft injury due to the small size of donor 
liver [13]. From an analysis of 16 clinical cohorts, the 
tumor recurrent rate is significantly higher due to the 
graft injury in living donor liver transplantation (LDLT) 
group compared with deceased donor liver transplantation 
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(DDLT) group [14]. In our recent studies, we have 
demonstrated the significance of acute phase graft injury 
on late phase tumor growth and invasiveness after liver 
transplantation in animal models [15]. The inflammatory 
response resulted from hepatic I/R injury not only 
provided a favorable environment for tumor growth, but 
also promoted tumor cell invasiveness [16]. Furthermore, 
chemokine (C-X-C motif) ligand 10 (IP10) was identified 
as a distinct gene signature of acute-phase graft injury 
and late-phase tumor recurrence after liver transplantation 
[17]. Post-transplant enhanced IP10 signaling in small-
for-size liver grafts not only directly promoted tumor cell 
proliferation and invasiveness [17], but also mobilized 
circulating endothelial progenitor cells into liver graft and 
further promoted tumor angiogenesis during liver tumor 
recurrence after liver transplantation [18].
IP10, as a secretory protein, is secreted by many 
types, including leukocytes, activated neutrophils, 
eosinophils [19], monocytes, epithelial cells, endothelial 
cells, stromal cells and keratinocytes in response to IFN-γ 
[17]. IP10 played crucial roles in interferon responses 
including attraction of activated lymphocytes, monocytes, 
T cells and NK cells to inflammatory area [20]. Highly 
expression of IP10 was found in infectious diseases, 
inflammatory [21, 22], autoimmune diseases [23], and 
variety of cancer diseases. IP10 and its downstream signals 
were considered to be potential therapeutic targets in 
attenuation of acute phase graft injury and prevention of 
tumor recurrence after liver transplantation using small-for-
size graft [17]. Increasing evidence suggested that ER stress 
was associated with graft injury and HCC recurrence after 
transplantation, but no studies specifically focused on the 
underlying mechanism [24]. It is worthwhile to explore the 
crosstalk between graft injury induced IP10 overexpression 
and the activation of ER stress after liver transplantation.
The endoplasmic reticulum (ER) is a specialized 
organelle that plays a central role in biosynthesis, 
correcting protein folding, and posttranslational 
modifications of secretory and membrane proteins. The 
activation of ER stress not only played important roles in 
graft injury during organ transplantation [24, 25], but also 
regulated cisplatin-induced cell death and drug resistance 
[26]. There are contradictory reports regarding the role 
of ER stress response in cancer [27]. Although there 
were indications that ER stress may provide protection 
against cancer [28, 29], plenty of examples suggested 
that the activation of ER stress signaling was essential for 
cancer cell survival and tumor recurrence [30, 31]. Tumor 
recurrence requires the residue circulating HCC cells 
which escaped from immune surveillance [32]. Recurrent 
HCC could also developed resistance to adjuvant 
therapies after liver transplantation [32]. However, the 
role of graft injury induced IP10 overexpression on 
post-transplanted chemoresistance is still unknown. 
As a distinct gene signature of acute-phase graft injury 
and tumor recurrence [17], IP10 might be the key factor 
bridging graft injury to chemoresistance in recurrent HCC 
after liver transplantation. IP10 neutralizing antibody 
might provide a potential adjuvant therapy to attenuate 
chemo-resistance in recurrent HCC.
In this study, we proposed that IP10 may promote 
cisplatin resistance after liver transplantation by activating 
ER stress signaling pathways. IP10 neutralizing antibody 
might sensitize cisplatin treatment in HCC.
RESULTS
Over expression of IP10 correlated with 
 chemoresistance genes in rat liver transplantation 
model
In rat liver transplantation model, IP10 was found 
to be overexpressed in tumor and liver tissues from small-
for-size group at day 14 and day21 (Figure 1A). Several 
multidrug resistant genes including ABCB1, ABCG2, 
Bcl-2, CFTR and STAT1 were also overexpressed in 
small-for-size group compared with whole graft group 
(Figure 1B–1C).
Higher circulating IP10 correlated with tumor 
recurrence in HCC recipients
Significant elevation of circulating IP10 expressions 
was observed at acute phase (day 1) after liver 
transplantation by comparing with that at Day 0 and Day 7 
(Figure 1D).
Circulating IP10 in recurrent group was significantly 
higher than that in non-recurrence group at day1 (677 ± 101 
pg/ml vs 341 ± 93 pg/ml, p = 0.027) and day 7 (204 ± 32 
pg/ml vs 123 ± 11 pg/ml, p = 0.039) (Figure 1E). Moreover, 
circulating IP10 expression in small-for-size group was 
significantly higher than that in whole graft group at day 
1 (251 ± 53 pg/ml vs 119 ± 10 pg/ml, p = 0.013) and day 
7 (251 ± 53 pg/ml vs 94 ± 11 pg/ml, p = 0.02) (Figure 1F).
IP10 induced cisplatin resistance in HCC cells
According to the expression level of IP10, six HCC 
cell lines were assigned into 2 groups, (1) lower IP10 
expressed group (LO2, PLC HepG2 and MHCC97L) 
and (2) higher IP10 expressed group (Hep3B and Huh7) 
(Supplementary Figure S3).
Extracellular function of IP10 on HCC cell lines
IP10 recombinant protein (r-IP10) was applied to 
elevate the extracellular concentration of IP10 in cell culture 
environment. Elevation of extracellular IP10 significantly 
promoted HCC cell proliferation (Supplementary Figure S2).
After 2 weeks of cisplatin administrated with/
without r-IP10, there was no significant difference of cell 
proliferation rate in HCC cell lines with high expression 
of IP10—Hep3B and Huh7 (Figure 2A). r-IP10 could 
significantly promote HCC cell survive in PLC and 
MHCC97L under different concentrations of cisplatin 
treatment (Figure 2B).
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Figure 1: Over expression of Multidrug resistant genes in rat liver transplantation model and the expressions of IP10 
in human liver transplantation. A. mRNA level of ABCB1 and ABCG2 in tumor and liver samples from rat liver transplantation 
model. *P < 0.05. B. mRNA level of AKT and BCL2 in tumor and liver samples from rat liver transplantation model. *P < 0.05. C. mRNA 
level of STAT1 and CFTR in tumor and liver samples from rat liver transplantation model. *P < 0.05. D. Representative images of up-
regulation of circulating IP10 in HCC patients at 1 day after liver transplantation. *P < 0.05. E. The association between tumor recurrence 
and IP10 expression level in clinical liver graft biopsies. *P < 0.05. F. The association between small graft ratio and intragraft IP10 
expression level in clinical liver transplantation patients. *P < 0.05.
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Figure 2: The effect of IP10 on HCC cell lines in vitro. A. The effect of rIP10 administration on proliferation of Hep3B and Huh7 
72 hrs by MTT assay. B. The effect of rIP10 administration on proliferation of PLC and MHCC97L under increasing concentrations of 
cisplatin for 72 hrs. *P < 0.05. C. The effect of cisplatin on proliferation of MHCC97L-3.1 and MHCC97L-IP10 was detected by MTT 
assay, *P < 0.05. D. The effect of cisplatin on proliferation of MHCC97L-3.1 and MHCC97L-IP10 was detected by colony formation assay. 
*P < 0.05. E. The effect of cisplatin on proliferation of PLC-3.1 and PLC-IP10 was detected by MTT assay, *P < 0.05. F. The effect of 
cisplatin on proliferation of PLC-3.1 and PLC-IP10 was detected by colony formation assay. *P < 0.05.
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Figure 3: The effect of IP10 on tumor growth and chemoresistance in Subcutaneous and Orthotopic nude mice models.  
A. The effect of IP10 stable transfectant (MHCC97L-IP10) on tumor formation under cisplatin treatment. The tumor volumes of each 
subcutaneous nude mouse model were recorded at the endpoint of this study. B. Tumor volumes were recorded each time after the cisplatin 
treatment. Representative images of tumor growth rate after cisplatin treatment. *P < 0.05 MHCC97L-IP10 vs MHCC97L-3.1 group. 
C. Representative images of tumor necrosis and tumor cell apoptosis by H & E and TUNEL staining in subcutaneous nude mice model (200×). 
D. Tumor volume at the endpoint of orthotopic nude mice model after cisplatin treatment. E. Representative images of significant higher tumor 
forming ability in MHCC97L-IP10 group under cisplatin treatment. *P < 0.05 MHCC97L-IP10 vs MHCC97L-3.1 group. F. Representative 
images of tumor necrosis and tumor cell apoptosis by H&E and TUNEL staining in orthotopic nude mice model (200×).
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Intracellular function of IP10 on HCC cell lines
The full length of IP10 was transfected into 
2 HCC cell lines (PLC and MHCC97L) with low IP10 
expression. The mRNA expression level of IP10 in stable 
transfectants were significantly higher than primary HCC 
cell lines, from 10 to 600 folds. Among them, PLC-IP10-3 
and MHCC97L-IP10-1, with high IP10 expression were 
chosen for further studies (Supplementary Figure S4).
Several multi-drug resistant genes including 
ABCB1, ABCG2 and CFTR were up-regulated in both 
PLC-IP10 and MHCC97L-IP10. Expressions of MAP7, 
STAT1 and AKT also showed higher expression in IP10 
stable transfectants (Supplementary Figure S5).
HCC cell proliferation rate was significantly higher 
in IP10 overexpression stable transfectant after 72 hours of 
cisplatin administration. When the concentration of cisplatin 
raised up to 9 μM, 12 μM and 15 μM, the percentages of 
viable cell of MHCC97L-IP10 was significantly higher 
compared to MHCC97L-3.1 (9 μM : 65.5 ± 5.7% vs 32.9 
± 6.6% , p = 0.027; 12 μM: 50.1 ± 4.3% vs 24.5 ± 1.9%, 
p = 0.019; 15 μM: 38.3 ± 9.1 vs 17.3 ± 6.4%, p = 0.035). 
The IC50 of cisplatin in MHCC97L-IP10 was around 1.6-
fold higher than MHCC97L (Figure 2C). This result was 
also confirmed by colony formation assay (Figure 2D).
The percentages of viable cell of PLC-IP10 
was significantly higher than PLC-3.1 under cisplatin 
administration (6 μM: 67.9 ± 10.1% vs 38.2 ± 4.3%, 
p = 0.04; 8 μM: 42.4 ± 2.7% vs 30.1 ± 4.0%, p = 0.035; 
10 μM: 39.1 ± 4.7% vs 13.2 ± 11.5%, p = 0.031). The 
IC50 of cisplatin in PLC-IP10 was around 1.5-fold than 
PLC-3.1 (Figure 2E). This result was also confirmed by 
colony formation assay (Figure 2F).
In summary, overexpression of IP10 significantly 
promoted HCC cell proliferation and colony forming 
ability in PLC and MHCC97L HCC cell lines.
IP10 promoted tumor growth under cisplatin 
treatment in animal models
In subcutaneous nude mice model
Average tumor volume from MHCC97L-IP10 
was significantly larger than the control group after 3 
weeks of cisplatin treatment (Figure 3A). Tumor growth 
rate was significantly higher in MHCC97L-IP10 group 
(Figure 3B). H&E and TUNEL staining demonstrated that 
tumor necrosis and tumor cell apoptosis was attenuated 
in MHCC97L-IP10 group (Figure 3C). These results 
demonstrated that IP10 overexpression could stimulate 
tumor growth and alleviate tumor necrosis, tumor cell 
apoptosis under cisplatin treatment.
In orthotopic liver tumor nude mice model
The tumor volume of MHCC97L-IP10 (268.3 ± 
109.3 mm3) was significantly larger than the control group 
(90.2 ± 60.5 mm3) at the end point of this study (p = 0.041) 
(Figure 3D–3E). Tumor necrosis and tumor cell apoptosis 
was attenuated in MHCC97L-IP10 group (Figure 3F).
In orthotopic liver tumor nude mice model with 
hepatic IR injury
One group of nude mice was subjected to half an hour 
ischemia before tumor implantation. Cisplatin was given to 
these nude mice 2 weeks after tumor nodule implantation. 
According to the optical imaging, tumor size from IR injury 
group was larger compared to the control group after 3 and 4 
weeks of cisplatin treatment (Figure 4A). The tumor volume 
was confirmed to be significantly larger in IR injury group by 
comparing with control group (14.9 ± 8.9 mm3 vs 65.5 ± 20.1 
mm3, p = 0.01) (Figure 4B). The circulating IP10 expression 
in IR injury group was around 1700 pg/ml which was 9-fold 
of its expression in control group (Figure 4C). The circulating 
IP10 in IR injury nude mice models was significantly higher 
than subcutaneous and Orthotopic models. (Subcutaneous-
IP10 group: 413.9 pg/ml; Orthtopic-IP10: 433.2 pg/ml; I/R 
group: 1672.3 pg/ml, p < 0.01) (Figure 4D)
In summary, IP10 overexpression was induced 
by hepatic IR injury. IP10 overexpression significantly 
promoted tumor growth and attenuated tumor cell 
apoptosis under cisplatin treatment.
IP10 activated ER stress signaling pathway
ER stress includes three main pathways. One of them 
functions as anti-apoptotic effect with the key molecules 
ATF6/Grp78, other two pathways promote cell apoptosis by 
the activation of PERK-CHOP and IRE1α. In order to reveal 
the correlations between IP10 up-regulation and the activation 
of ER stress, the expressions of these key molecules were 
investigated in in vitro, in vivo and clinical samples.
In in vitro experiments
MHCC97L-IP10 and MHCC97L-3.1 were 
administrated by different concentrations of cisplatin for 
2 weeks. The expression of IP10, ATF6, Grp78, PERK, 
CHOP and IRE1 were examined. The anti-apoptotic 
factors (ATF6/Grp78) were significantly up-regulated by 
Cisplatin treatment in MHCC97L-IP10 group. It implied 
that over-expression of IP10 may induce chemo-resistance 
in HCC cells. Expressions of pro-apoptotic factors (PERK/
CHOP) had a cisplatin dose dependant increasing in 
MHCC97L-3.1 group (Figure 5A). The expression of 
IRE1α did not have any significant difference.
In animal model
In nude mice liver tumor model with hepatic IR 
injury, Grp78 and ATF were found to be significantly 
overexpressed in tumor tissue. A positive correlation was 
observed between overexpression of IP10 and the activation 
of Grp78 and ATF6 (Figure 5B). However, expressions of 
PERK, CHOP, IRE1α and Caspase12 did not show any 
significant change (Supplementary Figure S5).
In clinical cohort
Intragraft IP10 was found to be overexpressed in HCC 
recipients, especially in the recurrent group (Figure 5C). 
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Figure 4: The effect of graft injury on IP10 expression of chemoresistance. A. Optical image of tumor growth at 3 and 4 weeks 
cisplatin treatment. B. Tumor volume at the endpoint of orthotopic IR injury nude mice model after cisplatin treatment. C. Representative 
images of significant higher tumor forming ability in IR injury group under cisplatin treatment. *P < 0.05 vs control group. D. Comparison 
of circulating IP10 expression level in Subcutaneous, Orthotopic and IR injury nude mice models.
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Figure 5: Activation of ER stress signaling pathways. A. Activations of ER stress pathways, including CHOP, ATF6 and GRP78 in 
IP10 overexpressed stable transfectant (MHCC97L-IP10) after cisplatin administration. Right panel: Western-blot. Left panel: quantification 
analysis. B. mRNA level of GRP78 in tumor tissue from I/R injury nude mice model. *P < 0.05 vs control group. C. mRNA level of ATF6 
in tumor tissue from I/R injury nude mice model. *P < 0.05 vs control group. D. mRNA level of PERK in tumor tissue from I/R injury nude 
mice model. E. mRNA level of CHOP in tumor tissue from I/R injury nude mice model. F. mRNA level of IRE1alpha in tumor tissue from 
I/R injury nude mice model.
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Consistent with the up-regulation of IP10, the expression of 
Grp78 and ATF6 were significantly increased in liver tissues 
from the patients with HCC recurrence (Figure 5D–5E). 
The expression of PERK and CHOP was also up-regulated 
in the recurrent group (Figure 5F). There was no significant 
difference in the expression of IRE1α and Caspase12 
(Supplementary Figure S5).
IP10 neutralization antibody sensitized cisplatin 
treatment
In in vitro studies
IP10 neutralizing antibody was applied as a 
combination treatment in PLC-IP10 and MHCC97L-IP10. 
HCC cell proliferation was significantly suppressed under 
cisplatin administration combined with IP10 antibody. The 
IC50 was significantly decreased in cells treated with the 
cisplatin and IP10 antibody (Figure 6A). IP10 antibody 
could also significantly suppress colony forming ability 
both in MHCC97L-IP10 and PLC-IP10 (Figure 6B).
In orthotopic nude mice liver tumor model
Fourteen days after tumor nodule implantation 
(Supplementary Figure S6), single cisplatin or combination 
with IP10 neutralizing antibody was given respectively. 
By comparing luciferin signal, the tumor growth was 
suppressed in IP10 neutralizing antibody combined 
with cisplatin group after 3 to 4 weeks of treatment. The 
tumor growth was significantly suppressed in combine 
treatment group by comparing with the cisplatin single 
treatment group (p = 0.012) (Figure 6C and Supplementary 
Figure S7). The treatment of cisplatin combined with 
IP10 neutralizing antibody significantly suppressed liver 
tumor growth by promoting tumor necrosis and apoptosis 
(Figure 6D). No obvious side effects related to IP10-
antibody were observed during the observation period.
DISCUSSION
IP10 plays a significant role in acute phase graft 
injury and has potential value to predict tumor recurrence 
after liver transplantation for liver cancer patients 
[17]. Overexpression of IP10 also contributed to HCC 
recurrence after liver transplantation through promoting 
of tumor cell proliferation and invasion, together with 
inducing angiogenesis by mobilization of circulating 
endothelial progenitor cells [17, 18]. In the current 
study, the acute phase up-regulation of IP10 was found 
to have significant correlations with graft injury and 
late phase tumor recurrent in HCC patients underwent 
liver transplantation. We firstly demonstrated that graft 
injury induced IP10 over-expression could promote 
cisplatin resistance in HCC cells by activation of ATF6/
Grp78 ER stress signaling pathway. IP10 overexpression 
could activate ATF6/Grp78 both in in vitro and in vivo 
experiments, and further validated in our clinical cohort.
We also illustrated that over-expression of IP10 in 
HCC cells significantly promoted HCC cell proliferation 
and colony forming ability under cisplatin administration 
in vitro. In animal studies, three animal models were 
established to elaborate the relationships among IP10, 
graft injury and cisplatin resistance. IP10 could promote 
tumor growth and alleviate tumor necrosis under cisplatin 
treatment in both subcutaneous and orthotopic nude mice 
models. By comparing these three animal models, the IP10 
up-regulation was induced by three different ways. Two of 
them were established by using IP10 stable transfectants 
and one was induced by IR injury. The result showed that 
the circulating IP10 expression was significant higher in 
IR injury model. In clinical samples, graft injury could 
induce the up-regulation of circulating IP10, which had 
significant correlations with HCC recurrent rate and 
small graft ratio. These data indicated that IP10 may 
have prognostic value to predict tumor progression and 
recurrence. It also confirmed the significant effect of 
IR injury on IP10 overexpression which could further 
promote tumor growth and invasiveness under cisplatin 
treatment. Cisplatin-induced DNA damage activates 
various signaling pathways to prevent or promote cell 
death, predominantly via apoptosis [33]. It was recently 
demonstrated that cisplatin could induce endoplasmic 
reticulum stress (ER stress) and non-nucleus-dependent 
apoptotic signal activation [34]. Currently, ER stress was 
considered to play crucial roles in cisplatin-induced tumor 
cell death as a cell stress signaling receptor. By examining 
the correlations between IP10 and the activation of ER 
stress, we may understand the underlying mechanism of 
IP10 overexpression induced chemo-resistance in HCC.
ER stress was regulated by the unfolded protein 
response (UPR) system. When the unexpected unfolded 
proteins were limited in the tolerable range, the UPR 
system could activate to restore the balance. If the stress 
was continuous, the UPR system could not restore the 
balance in prolonged ER stress and conduct programming 
death itself [35]. However, cancer cells could adapt to 
chronic stress in the tumor microenvironment by inducing 
the expression of GRP78/BiP, a major endoplasmic 
reticulum chaperone and anti-apoptotic properties. 
These residue cancer cells were responsible for tumor 
recurrence and associated with an unfavorable prognosis. 
In this study, IP10 was identified to play a key role in 
mediating the activation of ER stress and assisting post-
transplant HCC cell survival via ATF6/Grp78 in our 
in vitro and in vivo experiments, further validated clinical 
samples. Graft injury induced IP10 overexpression was 
firstly demonstrated to be significantly correlated with the 
activation of ATF6/Grp78, which were key molecules in 
the anti-apoptotic pathway of ER stress signaling. IP10 
might urge HCC cell survive from the ER stress and 
these cells might become more aggressive and resistant 
to chemotherapy due to the activation of ATF6/Grp78. 
However, several other proteins were also found to be 
Oncotarget28051www.impactjournals.com/oncotarget
Figure 6: IP10 neutralization. A. The effect of IP10 neutralizing antibody combined with cisplatin on proliferation of PLC and 
MHCC97L after 72 hrs was detected by MTT assay. *P < 0.05 vs cisplatin single treatment group. B. The effect of IP10 neutralizing 
antibody and cisplatin combined treatment on proliferation of PLC and MHCC97L by colony formation assay. *P < 0.05 vs cisplatin single 
treatment group. C. The comparison of tumor volume at the endpoint of orthotopic nude mice model after cisplatin combined with IP10 
neutralizing antibody treatment. *P < 0.05 vs cisplatin single treatment group. D. Representative images of tumor necrosis and tumor cell 
apoptosis by H & E and TUNEL staining in orthotopic nude mice model with cisplatin and IP10 neutralizing antibody treatment (200×).
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up-regulated by graft injury, such as GRP19, IL-6 and 
HSP70 [17]. It will be worthwhile to investigate the 
role of those graft injury related genes on the late phase 
consequence after liver transplantation.
To date, more and more neoadjuvant therapies 
including the neutralizing antibodies, were applied 
as single or combined treatment for variety of cancer 
diseases. As an example, VEGF antibody (Bevacizumab) 
was found to have anti-tumor effect on colorectal 
cancer and HCC [36, 37]. Moreover, Bevacizumab 
was demonstrated to be an efficient adjuvant therapy to 
sensitize chemotherapy and achieve better outcome in 
advanced colorectal cancer and HCC [37, 38]. In this 
study, we firstly demonstrated that IP10 neutralizing 
antibody could be an efficient combination treatment 
to sensitize cisplatin treatment both in vitro and in vivo. 
It suggested the therapeutic potential of IP10 antibody 
treatment for HCC patients. However, the effect of IP10 
neutralizing antibody was only investigated on cisplatin 
in current study. It will be worthwhile to further explore 
the application of IP10 antibody on other chemodrugs 
including 5-FU, doxorubicin and others. Additionally, by 
thorough understanding of the interaction between IP10 
and ER stress activation, the downstream targets such as 
ATF6 and Grp78 will also have a potential value to be 
further studied whether they could sensitize chemotherapy 
and achieve a better outcome.
In conclusion, acute phase liver graft injury could 
induce the overexpression of IP10 which responsible for 
cisplatin resistance via ATF6/Grp78 ER stress signaling 
pathway. IP10 neutralizing antibody could be a potential 
adjuvant therapy to sensitize cisplatin treatment. It will 
provide a new angle for attenuating early-phase graft 
injury and the treatment of recurrent HCC patients.
MATERIALS AND METHODS
Clinical association study
Clinical specimens
The study was approved by the Institutional 
Review Board of the University of Hong Kong / Hospital 
Authority Hong Kong West Cluster.
Fifty HCC patients (30 patients within and 20 
patients beyond Milan criteria; 36 patients within and 
14 patients beyond UCSF criteria) who have undergone 
liver transplantation between May 2001 and April 2009 
were recruited with informed consent from Department 
of Surgery, Queen Marry Hospital, The University of 
Hong Kong. Among them, 20 HCC patients had tumor 
recurrence after liver transplantation. Plasma samples 
were collected one day before the liver transplantation 
and 1 day, 7 days after liver transplantation. All 
these plasmid were stored at −80°C. Forty-eight liver 
samples were collected at 2 hours after portal vein 
reperfusion during surgery. Four donor samples were 
used as normal liver control. Patients with tumor 
recurrence were classified as tumor recurrent group. 
Other patients without tumor recurrence were assigned 
to non-recurrent group.
Animal models
Animals
Male inbred Buffalo rat weights from 280 ~ 350 
g were applied as donors and recipients for rat liver 
transplantation model. Male nude mice around 4~8 
weeks old and weights from 20 ~ 25 g were applied for 
orthotopic and subcutaneous xenograft nude mice models. 
These buffalo rat and nude mice were housed in a standard 
laboratory environment with sufficient water, chow and 
free activity. They were kept under constant environment 
with a 12-hour light/dark cycle. They were fasted 12 hours 
before operation. All the operations were performed under 
sterilized condition. All the animal studies were approved 
by the Committee on the Use of Live Animals in Teaching 
and Research (CULATR), The University of Hong Kong.
Rat liver transplantation model
The procedure for the donor operation was described 
in our previous study [18].
Xenograft ectopic nude mice liver cancer model
Xenograft subcutaneous nude mice model was 
established to study the role of IP10 on induction of 
cisplatin resistance. Method was described in previous 
study [39]. All the mice were segregated randomly and 
six mice were recruited in each group.
Xenograft orthotopic nude mice liver cancer model
In order to study the effect of IP10 neutralizing 
antibody, an orthotopic nude mice model was established 
to compare the effect of cisplatin treatment alone and IP10 
neutralizing antibody combined treatment (Supplementary 
Figure S1). All the mice were segregated randomly and six 
mice were recruited in each group.
Orthotopic nude mice liver cancer model with 
MHCC97L-3.1, MHCC97L-IP10 or MHCC97L-luc cell 
was established to observe the tumor growth under regular 
cisplatin treatment. Briefly, approximately 1 × 107 cells in 
0.2 ml of a culture medium were injected subcutaneously 
into the right flank of Balb/c nude mice. The mice were 
observed daily for signs of tumor development. Once 
the subcutaneous tumor had reached 1 cm in diameter, 
it was removed and cut into 1–2-mm cubes, which 
were then implanted into the left lobe of another group 
of nude mice (4 weeks old) [25]. Cisplatin or cisplatin 
with IP10 antibody treatment started at 2 weeks after 
the implantation. All the nude mice were segregated 
randomly. Four milligrams per kilogram cisplatin with/
without 0.5 milligrams per kilogram IP10 antibody was 
injected intraperitoneally into the nude mice every 4 days 
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and lasted for 4 weeks. Finally, the mice were anesthetized 
by intraperitoneal injection of pentobarbital (Abbott 
Laboratories Chicago, IL, USA) at a dose of 50 mg/kg. 
The volume of the tumors was measured and calculated 
(Volume = 1/2 × Length × Width2). The liver and tumor 
samples were collected and preserved in formalin and 
liquid nitrogen.
In order to simulate graft injury induced 
IP10 overexpression and its effect on developing 
chemoresistance in HCC, an orthotopic nude mice liver 
cancer model with hepatic IR injury was established.
Nude mice liver cancer model with hepatic IR 
injury (IR injury group) was established by using 
MHCC97L-luciferase HCC cell line, the luciferin 
signal was examined by the Xenogen IVIS® in vivo 
imaging system [25]. For the I/R injury group, the 
portal vein was clamped for 30 minutes to mimic the 
ischemia period during liver transplantation. After the 
30 minutes ischemia, the tumor nodule with positive 
luciferin signal was implanted into the left lobe of liver. 
It has been demonstrated that the liver injury could 
not be obviously detected if the ischemia period was 
less than 30 minutes in our preliminary experiment. 
Generally speaking, 45 minutes could be applied for 
establishment of partial ischemia model [40]. However, 
the mice could not tolerate the surgical treatment if the 
ischemia period is too long in this study. Therefore, 
we selected 30 minutes as ischemia period. Cisplatin 
treatment started 2 weeks after the implantation. 
Tumor size was compared at 3 weeks and 4 weeks 
after cisplatin treatment by the Xenogen IVIS® in vivo 
imaging system. After 4 weeks treatment, the mice were 
sacrificed and tumor samples were collected for further 
analysis.
In vitro functional study
Cell culture
Human liver cancer cell lines (HepG2, Hep3B and 
Huh7) and human liver cell lines (MIHA and LO
2
) were 
purchased from the American Type Culture Collection 
(Manassas, VA, USA). The metastatic human liver cancer 
cell line MHCC97L was a gift which given from the 
Liver Cancer institute and Zhongshan Hospital of Fudan 
University, Shanghai, the People’s Republic of China. All 
cells were grown in Dulbecco’s modified eagle medium 
(DMEM) containing 10% FBS, 2 mM L-glutamine, 
100 units/ml of penicilium and streptomycin (Life 
Technologies, Carlsbad, CA, USA).
Cell transfection and selection of stable transfectants
Full length of IP10 and PCDNA3.1(+) were 
transfected into PLC and MHCC97L, cell transfection was 
performed as previously study described [39]. The stable 
clone of MHCC97L-IP10 was selected using G418 at 
0.4 mg/mL and the stable clone of PLC-IP10 was selected 
using G418 at 0.6 mg/mL. The selection period was 
4 weeks and expression of target gene was confirmed 
using qRT-PCR and Western-blot.
3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay
In order to explore the proliferation rate of HCC 
cells, MTT and colony formation assay were performed 
as previously described [39].
Colony formation assay
Colony formation assay was performed to compare 
the colony forming ability between different cell lines 
or with different types of drug administrations. Culture 
medium was changed every 3 days. After 2-week 
incubation, the colonies were washed with 1X PBS and 
fixed in 4% paraformaldehyde in 1X PBS. They were then 
stained with 0.5% crystal violet for 10 minutes at room 
temperature. The colonies were counted under a light 
microscope. The mean number of colonies was obtained 
from three independent experiments.
The function of rIP10 in HCC cell lines
Colony formation assay was performed to 
investigate whether the overexpression of IP10 in HCC 
cell lines could promote cell proliferation under the 
cisplatin environment. IP10 recombinant protein was 
applied to study the extracellular function of IP10 in HCC 
cell lines including Hep3B, Huh7, PLC and MHCC97L. 
Cells (5 × 103cells/well) were seeded onto 6-well plates 
and incubated with different concentrations of cisplatin 
for 2 weeks. For the treatment group, 0.5 μg/ml IP10 
recombinant protein was added into each well.
The intracellular function of IP10 in HCC cell lines
To investigate the intracellular function of IP10, 
IP10 overexpressed stable transfectants, PLC-IP10 and 
MHCC97L-IP10 were employed in colony formation 
assay.
The function of IP10 neutralizing antibody
To investigate the function of IP10 neutralizing 
antibody, MHCC97L-3.1 and PLC-3.1 with cisplatin 
administration alone were applied as the control groups. 
Meanwhile, MHCC97L-IP10 and PLC-IP10 with single 
cisplatin administration were also applied. MHCC97L-
IP10 and PLC-IP10 with cisplatin and IP10 neutralizing 
antibody were considered as the combination treatment 
groups. The concentration of IP10 antibody for in vitro 
study is 0.5 μg/mL. The concentration of IP10 antibody 
was applied according to the manufacturer’s instruction.
Real time quantitative reverse transcription 
polymerize chain reaction (qRT-RCR)
The mRNA level of IP10 was determined by qRT-
PCR as previously described [17]. The internal control was 
18S ribosomal RNA (18S rRNA). The sequences of primers 
used were listed in Supplementary Table S1, S2 and S3.
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Enzyme-linked immunosorbent assay (ELISA)
The plasma samples were diluted 800 times and the 
medium for cell culture was without any dilution before 
detection. The concentration of IP10 was tested using 
ELISA kit according to instruction manual (AdipoGenInc, 
Incheon, Korea).
Hematoxylin and eosin (H & E) staining
H&E staining was performed to determine the tumor 
necrosis in animal models. Method was described in our 
previous study [39].
TUNEL assay
TUNEL staining was performed to determine 
the tumor cell apoptosis in animal models. Method was 
described in our previous study [39].
Statistical analysis
The χ2 test was used to compare discrete variables. 
Independent-samples T test was used for comparison of 
continuous variables. P < 0.05 was considered to be statistically 
significant. Calculations were performed using SPSS computer 
software version 13 (SPSS, Chicago, IL, USA).
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